AnteoTech Limited (ADO) Earnings Call Transcript & Summary

August 28, 2025

Australian Securities Exchange AU Materials Chemicals earnings 36 min

Earnings Call Speaker Segments

Operator

operator
#1

This is AnteoTech's investor update, coming after the full-year results went out to the ASX yesterday and the investor presentation that was posted on the ASX platform this morning. Joining us from the company today is Merrill Gray, the recently appointed Managing Director and CEO, and she'll walk us through the presentation showing on your screen. A quick reminder — if you'd like to ask something, just send it in using the Q&A button located at the bottom of your screen, and we'll try to work through as many of those questions as we can. So with that, Merrill, over to you. Thanks.

Merrill Gray

executive
#2

Thanks, Simon. I'd like to welcome everyone to AnteoTech's Investor Update for the End of Financial Year 2025. It's a real honor and a thrill for me to be with you today, having officially taken on the MD/CEO position this month. When you last saw me, I was roughly 10 days into the interim job, and I can tell you it's been extremely busy since then. Obviously, we released the strategic review, in which we restructured and removed approximately $1.6 million in costs from the business. We've placed a very, very strong and serious emphasis on managing cash, with a corporate cost reduction program that continues, and we sped up the return of our R&D tax rebate, which came to $2.6 million. I want to thank the team for all the work that went into that. As part of moving forward, we've altered our approach to going to market. It's been fairly substantial, and there's more work ahead on our journey, but we now have greater segmentation of our markets and greater productization, and you'll all have seen that with the Ultranode, where we stepped out the various Ultranode formulation technologies we offer. We've refreshed our collateral. You'll also have seen that in the white paper for the Life Sciences business unit that's available on our website, and we're preparing a similar document for our batteries business.

Merrill Gray

executive
#3

Every bit of this reflects a cultural transformation we're pursuing so that we become far more commercial and sales-driven as an organization. A new CRM is being implemented, and it's going to support us as we keep moving along that path. The key point is that what we pledged to do, we have delivered, and we're still delivering it. We've moved into new markets — the U.S. market and South Korea. We'll give you a little more detail on those shortly. We have kept going, and we continue to keep going, in places where our markets are already established. India, clearly, very strongly from a life sciences perspective, and Europe through our battery business. I didn't want to step into the ongoing MD/CEO role until we had a genuinely clear focus and plans set and in motion, with the whole team working toward them. That's essentially where things stand. Across the last 12 weeks, the company has seen substantially greater interest from customers, from potential partners, from potential strategic partners, and around new products. On the whole, AnteoTech is on a better path and has a bright future in front of it. Today, I've picked out for you several key slides from the slide pack we released this morning. What I'll do is walk you through that now, and then we'll take questions.

Merrill Gray

executive
#4

Here's the agenda I want to walk you through. As a bit of a baseline, or a refresher for anyone who's followed our story for some time: AnteoTech is a chemicals and materials business that operates and sells on a global scale. Our customer base keeps growing, and as a company we've reached the commercialisation and revenue stage. People often ask me what our expertise really is — what do you actually focus on, what's your core competency? That competency sits in how we apply chemicals — cross-linking binders that are patent-protected — across a variety of industries. Naturally, our focus is life sciences and the batteries market. The crucial point here is our ability to create very strong bonds at the molecular level, molecule to molecule — in life science the term is bioconjugation — and molecule to surface, or substrate. We're a team of 24, mostly located in Brisbane, made up of scientists, sales professionals and commercial analysts. As I get out into the market and spend more time with customers and prospective strategic partners, I hear that we're recognised as leaders in the fields we operate in.

Merrill Gray

executive
#5

To wrap up the recap and focus specifically on life sciences: through AnteoBind and AnteoBind NXT, what we provide and what we do is cut our customers' costs by lowering antibody consumption as well as new tests and new test development. Manufacturing costs can also come down by enhancing workflow and assay reproducibility. A key point here is that, for instance, at the Serum Institute of India, quality control across very large vaccine batches relies on our product. Another important thing on the life sciences side is that our product can be extremely specific — highly specific — and sensitive, which in modern medicine and in the creation of modern vaccines enables reproducible use and allows key decisions to be made about people entering manufacture. Turning to batteries, our AnteoX product enhances high-silicon anode performance and, consequently, battery performance. We are in constant conversation with people about the next generation of batteries and where high silicon fits from a competitive advantage standpoint regarding production cost, performance, supply access, raw materials, and global availability of the raw materials we use — the silicon we use.

Merrill Gray

executive
#6

We lower the expenses for additional additives that may be incorporated into the anode, such as carbon nanotubes and binders. Regarding Ultranode — and I have Ultranode X right here — as everybody is aware, we offer a variety of Ultranode formulations. We collaborate with extremely high-content silicon and aim for 30% gains in energy density. For instance, that is highly meaningful when it comes to extending how far electric vehicles can drive on a battery pack of the same size. It can result in our having smaller or lighter batteries, plus quicker charging and longer run times. In our strategic review, the blue represents where we already stood, the markets we were already present in, and the pink shows what we have now extended into. That has happened on a highly targeted basis. In India, Serum Institute of India is our major client, and we keep working with the Serum Institute of India. We are using — we have been accepted into the export growth programme by Oztrade. We will be using Oztrade, and we are already collaborating with Trade Investment Queensland on expanding our channel, our pipeline, and our customer base. We will also work in the battery space in India. Up to now, that has not been our focus. We have concentrated on the U.S., where we have done the Black Diamond Structures.

Merrill Gray

executive
#7

We have a joint development agreement involving carbon nanotubes, and I’ll get to that shortly. On the battery side in South Korea, we’ve made an announcement—we already have a life sciences distributor there, but we’ve announced Camsun as a distributor. I was just on a call with our battery team and their team about how we plan to proceed there. In Europe, we’re still working with Weon and other battery makers. On life sciences, we’ve re-engaged with some very large big pharma companies regarding certain products of ours and products we may develop. As for operational highlights this year: Black Diamond Structures, a joint venture, has a joint development agreement focused on pairing AnteoX with the carbon nanotube dispersion technology they possess. In early October, we’ll visit Austin, Texas, where their plant is located, as part of attending the Detroit Battery Fair, Battery Expo—we won’t be exhibiting there, but we plan to meet a range of prospective customers, and that’s a major focus for us. Regarding Weon, trials of Ultranode remain in progress. It’s a highly structured program. There’s potential for Ultranode to enter commercial production for their miniature batteries, wearables, and one customer in that area is Cochlear.

Merrill Gray

executive
#8

We are quite happy to report that we've hit major performance milestones for our Ultranode X product and formulation—the technology formulation—reaching nearly 900 cycles at 80% capacity with the 70% silicon anode. We're extremely pleased to have gotten there, and we know the path to what the industry regards as the benchmark of 1,000. On the life sciences side, things have also gone well with the Serum Institute of India, and in fact we've been getting orders exceeding what we expected under the five-year contract signed early in this financial year. We keep working with Vidcare, a startup, and what makes us especially keen and enthusiastic there is that it's a platform. Getting into Vidcare as a trusted supplier could unlock the door to quite a few different applications. That matters a great deal to us. As I mentioned, since the financial year ended, we announced Camsun to support us in South Korea and to build on the people who are already parties that have contacted us and their extensive distribution base. We're truly looking forward to collaborating with them, and we've already had some good discussions.

Merrill Gray

executive
#9

MOBIUS — that's short for Molecular Biosensor at Point of Use. This month saw the launch of the MOBIUS Australian Research Centre Hub, with La Trobe University serving as its primary host. John Brumby opened it, it has drawn substantial funding, and we became the first industry participant at that centre. It sits squarely within our sweet spot, we're delighted to be part of it, and we're eager to see how — given their work, namely research, biosensor development, and commercialization — we can engage in a truly meaningful way and leverage what happens there. What I'd like to turn to now is a few high-level financials. On cost, we achieved a genuine 10% reduction, and as I mentioned, we pulled forward our R&D tax rebate. Clearly, cost remains a very sharp focus for us, and we're pursuing additional cost reductions across the coming financial year. On revenue, we doubled it, and we're very pleased to report that, naturally, we're doing everything. Every effort goes toward continued growth in our revenue profile. At this stage, I'd like to wrap up by noting that we hold this chemical binding platform technology applicable across multiple industries, along with our products in life sciences — AnteoBind and AnteoBind NXT — and then in batteries, AnteoX and our technology, Ultranode.

Merrill Gray

executive
#10

Every one of them is centered on boosting performance and reducing manufacturing expenses for our customers across various applications. That is their purpose, it is what we provide, and it is what our messaging keeps getting refined around. Our value proposition is clearly tailored to that specific end application. Our emphasis is on bringing products to market and expanding sales revenue. Certainly, during the last few months we have witnessed foundational shifts concerning our people, our systems, and the methods we use to support this faster commercialization. We possess a robust pipeline of opportunities—sales opportunities—and we are collaborating with strategic partners, which I would like to turn to next. For life sciences, our growth plans involve sustained expansion in India, in growing markets like South Korea—where we already work with Camsun—the U.S., and Japan. We are devoting considerable effort to strategic partnerships and possible new strategic product collaborations and partnerships in Europe with some large chemical companies, including large pharma, big pharma. We are examining China potentially with the right partner and under the proper terms and conditions. We are approaching that very carefully and judiciously. That is the kind of jurisdictional focus, and then in terms of the actual products.

Merrill Gray

executive
#11

We’re seeing growth in vaccine development, in our product being used for vaccine development, and in our product being used for quality control around vaccines and in lateral flow diagnostic tests. That’s what we do now—growing that alongside other companies is where our focus is. There are opportunities for us to expand into applications in pharmaceuticals, in targeted drug delivery, and in biotechnology around refining, bio-refining, and immunoassays around multiplexing and ELISA chemoluminescence. We’ve already begun to move, but we’d love to see—and we believe there are pipeline opportunities for us to move into animal use of our products and to work within an animal application. On lateral flow tests, we look forward to being able to let everyone know about progress there. Through MOBIUS, we believe there’ll be some opportunities when it comes to biosecurity for AnteoBind to be used. What does the pipeline look like? As you can see, from a leads perspective, there’s a heavy India focus. When it comes to AnteoBind and AnteoBind NXT, the split is around 80 to 20. What we’re focusing on here is expanding the lead pipeline and then systematically moving those leads through and converting them into sales. Similarly, how does that look for advanced battery technology?

Merrill Gray

executive
#12

Our emphasis is on U.S. growth built off the BDS joint development agreement, and defense and security applications are really where we're concentrating our efforts to try to lock in opportunities. We also want growth in South Korea, India, and China, though on a very structured and judicious basis. That's how we see it jurisdictionally. What does that mean product-wise? AnteoX is our product and our focus. AnteoX already combined with carbon nanotubes in joint development is the direction we've taken. Binders, new binders — new binder technologies have been developed — and potentially in separators too. It can be used inside the battery in a range of different ways. From an Ultranode standpoint, obviously Weon is a key focus for that to succeed, but also for us to get other companies that are looking to use Ultranode formulations into end product commercial rollout. On the strategic partnership side, while we announced that we would not proceed with the Queensland government grant that was offered to us, we were able to retain the opportunity to take on, or to progress, the ARENA grant, which is worth around $4 million, for a strategic partner that might want to work with us on an Ultranode X product development.

Merrill Gray

executive
#13

How is that pipeline shaping up for our advanced battery technologies business unit? We've put substantial effort into growing the leads—the count of leads we've generated via conferences and networking. At this point we're investing heavily in resources to advance those leads in an organized way, prioritized and structured quite deliberately around converting sales through the pipeline. The division between AnteoX and Ultranode is becoming visible, and within that we also have suppliers who might be customers too, along with strategics. The geographic distribution is visible as well. We've had a presence in Europe for some time. We're now moving in earnest into the U.S., India, and China. We receive many inquiries from China by way of South Korea, and that's where we anticipate seriously broadening this further across the months ahead. Regarding strategic partnerships, unsurprisingly, the kinds of parties we're engaging with include chemical and materials companies, diversified multinationals, battery manufacturers, and big pharma. Our aim is to figure out how to structure that so it adds meaningful value as the company progresses. To sum up, we're highly focused on commercializing our products and increasing sales revenue. As I mentioned, India, South Korea, and the U.S.A. are our focus right now.

Merrill Gray

executive
#14

What we're focused on is bringing new life to relationships and widening our sales pipeline. Getting into China on suitable terms alongside a suitable partner is something that could happen. With a pipeline of opportunities, we're in a strong position, and converting those into sales will require effort and expertise. Looking ahead, we're well placed to succeed. At this point I'll give it back to Simon. Taking questions is something I'm very happy to do.

Operator

operator
#15

Thanks a lot, Merrill — that’s great. One quick note: if you’re interested in posing a question, feel free to send it using the Q&A button located at the bottom of your Zoom window. We’ll address several of the questions that have come in. Will carbon nanotubes be functionalized using AnteoCoat or Bind?

Merrill Gray

executive
#16

Will they get functionalised? Regarding the product we're creating, the offering related to it concerns the way AnteoX interacts with the carbon nanotube. Black Diamond Structures is, in fact, a dispersion technology company. They buy carbon nanotubes. What matters is the dispersion and the functionality of those carbon nanotubes. Our product offering is that AnteoX potentially enables lower consumption of carbon nanotubes, which are very costly, along with better performance. It really has more to do with — you're asking me, is it coating or is it dispersion? From where I sit, it's more about dispersion and electrochemical conductivity. I hope that answers the question.

Operator

operator
#17

All right, thank you, Merrill. I just have one more question to ask. Is AnteoX going to be applied toward enhancing lead acid batteries?

Merrill Gray

executive
#18

No — high-silicon anode is where we're entirely focused. There's just one minor caveat. Whenever opportunities present themselves, we'll always go after whatever serves the company's best interests. Very recently, a polymer cathode company was brought to our attention. They've either already bought a sample from us or are currently buying one. We're quite enthusiastic about what a combination of a polymer cathode and a high-silicon anode could allow us to achieve. So to answer that, high-silicon anodes are our focus.

Operator

operator
#19

Thanks, Merrill. Is Burnett Diagnostics Institute in talks with AnteoTech?

Merrill Gray

executive
#20

Not to my knowledge. A lot of what we do is heavily international in nature. We've been speaking with several very well-known research groups in laboratories, and we're looking forward to sharing more on that down the road. Our door is always open, and in fact we sell a substantial amount of AnteoBind into labs throughout Australia and New Zealand. The catch is those volumes can be fairly small. It comes down to how we engage — whether that lab is out there promoting our product, putting our product to use, or seeking to collaborate with us. There are all sorts of different routes, but that particular one isn't something I'm familiar with.

Operator

operator
#21

Alright, thank you, Merrill. I'm simply keeping in mind that this company doesn't provide guidance, but I do have a question about future revenue. Could you give us some indication of when significant revenue will come in?

Merrill Gray

executive
#22

Alright, what I can tell you is that, as I mentioned during the presentation, that's where the attention is. As for the details of when that might or might not land and how it will play out, we aren't in a position to provide that. I think after speaking with the team before coming here, it's really important to convey that everyone is doing all they can to make this happen and to speed things up when it comes to sales execution. I suppose that's my response to that question. We're pushing as hard and as fast as we possibly can.

Operator

operator
#23

Great, I appreciate that. I have one question. Could you give us an update on where things stand with EV1, EV2, EV3, and so on?

Merrill Gray

executive
#24

Okay, alright. Yes, that is a fair question. What we have been trying to get across is that our attention is firmly on Ultranode and what its potential might be. It has the chance to be revolutionary. It could become something truly significant — of that there is no question. Several dimensions are involved here. The prior question concerned lead-ion batteries. Looking at it from a Lithium-ion battery angle, silicon anodes demand that people — most of the industry still operates below 10% silicon, while we are far ahead at 70% and 95%. Let me just tell you, a kind of threshold exists, and a journey exists — that is likely a better way to describe it — that people must undertake and grasp how the type of silicon we utilize in Ultranode is easily obtainable. At volume it can be inexpensive, and by shifting into high silicon anodes, we tackle certain problems related to swelling, we tackle critical problems related to swelling, and you get all the advantages that silicon provides. The response to that question is that we perceive enormous opportunity ahead around high performance, high silicon anodes. The catch is that we must guide the market through and carry the market along with us, and Ultranode X is going to need additional investment.

Merrill Gray

executive
#25

We get that. We're still pushing forward on it at a very low cost, but we've been upfront that this will need a strategic partner who is entirely dedicated to that significantly higher energy density — basically the kind of high silicon anode that knocks it out of the park at that performance level. Through the performance milestones we achieved this year, we've demonstrated that we're right there, yet getting seriously into the EV market will take further investment from us. During the strategic review we made it clear that we have formulations and an opportunity to generate revenue from what we've already tested, and we're working to capitalize on that and create sales opportunities. That's the answer to that one. It's the European EV market. We've been clear about that. It is quite difficult, and hence the South Korean approach, and we'll be looking to leverage everything we've done into there.

Operator

operator
#26

Okay, that brings us to the next question. Could you elaborate a bit more on the relationship with Camsun, the Korean distributor, and how you expect that to develop?

Merrill Gray

executive
#27

Yes, all right. How we see this progressing is that it actually arose from an introduction made by a client—or a client connected to something we're working on. There are several parties in South Korea with whom we've been holding discussions. The thinking was that having a local representative would help us speed up our vision for sales in that country across AnteoX, potentially AnteoS on the separator side, and Ultranode as well. We believe those talks have gone quite well. We feel they already have a customer base in batteries, and we intend to collaborate with them in a creative and swift manner. It was really about being on the ground, understanding the market, tapping the existing customer base, and figuring out how we can get in there—and so far, so good.

Operator

operator
#28

Thanks, Merrill. Is our attention now shifting more toward partnering with battery makers instead of EV firms, and if that's the case, what's driving that shift in direction?

Merrill Gray

executive
#29

Yes, I'd say that's right — the answer is affirmative. The reason is that we've broadened where we're aiming, across a range of applications; Weon, naturally, is wearables. We're likewise engaged with a business involved in consumer goods for mobile phones. Now, without getting too carried away about that, they still need to run testing and work through assessments of new commercial products, and there's a timeline attached to that. Drones are a big area of emphasis for us, and we perceive a very substantial opportunity for Ultranode there when it comes to lighter. It's also a question of what the use case is for unmanned aircraft and drones, biosensors, and a whole variety of other things. Essentially, we believe Ultranode has the potential to extend into those products. Coming back to EVs — sorry, the point was about why we aren't solely in EVs. Was that the one?

Operator

operator
#30

Apologies, just a moment. So then, what explains the shift in focus away from EV companies and toward battery manufacturers?

Merrill Gray

executive
#31

Battery makers. Yes, still battery makers, though ones serving various applications. What's the reason? One of the backup slides I have — it's actually in the deck distributed today — shows just how intricate the supply chain is. We're a single component, and we must be involved while battery makers are carrying out design work on the next generation of batteries. That's the takeaway you get from companies such as Mercedes-Benz, or whichever manufacturer you happen to engage with. They don't build batteries themselves. They can specify or establish the standards or design parameters they'd prefer, but even so, it's the battery manufacturer — companies like CATL — that is actually doing the battery design work. For us, to secure volume, and over the longer term to grow sales value, we need to be positioned right at the source where design work is taking place and where decisions get made. That's really the bottom line.

Operator

operator
#32

Great. You just brought that up, but are discussions with Mercedes still ongoing, or has that relationship ended at this point?

Merrill Gray

executive
#33

No, we have a solid relationship that continues, and they're always going to care about what we're able to provide for them when it comes to lowering costs and improving performance. From what I gathered at the most recent meeting, they are sharply focused on costs, and they understand that what they're doing fits inside their own parameters, but that relationship is something we'll keep up. It's a strong relationship. We'll keep it going.

Operator

operator
#34

Thanks. So when it comes to closing deals, what would you say are the biggest obstacles you keep running into?

Merrill Gray

executive
#35

We operate in two complicated sectors. As I mentioned, in the supply chain we're just a small piece with AnteoX inside a highly intricate system. Securing a foothold, gaining visibility, and obtaining the chance — that's the focus of our efforts around segmentation and targeting, ensuring we speak with the appropriate individuals, the decision makers able to grant us the opening to demonstrate our capabilities. The primary obstacle is simply that it takes time, and in some of these areas — in the two business units we're in — people are quite guarded. Take batteries: a company may reach out because they'd like to use our product, and we'd like to offer guidance based on what we know, since we genuinely know a great deal and have witnessed a great deal, yet they aren't so inclined to share. Considerable time can pass if we're unable to truly steer them on the best way to apply our product. There's a kind of circularity at play. How we navigate around that, and how we ensure we're genuinely presenting a new offering — Support Lite — through which we can supply a sample, share lessons drawn from our experience base, and provide remote assistance while they use that product in their own laboratory.

Merrill Gray

executive
#36

So what happens, Simon, is that even when we've done the testing and they've handed over every material and component showing how their battery is assembled, they still insist on giving it a go on their own. That process can be drawn out. In my view, it may run three months for folks to test cells in the configuration they prefer and with the chemistry they're after. So how do we speed that up, right? We're putting relentless effort into finding ways to make it better.

Operator

operator
#37

Okay, so can you give us any guidance on when that magic milestone might be reached — 1,000 cycles at 80% retention for the battery technology?

Merrill Gray

executive
#38

Right, so we did actually release — I'm certain we released one of our newest versions, the Queensland one, that's correct — where we've partnered with parties in Australia that are well known and well regarded, capable of performing single-layer as well as multi-layer pouch cell testing. We're running a program aimed at reaching that 1,000 cycles. We've taken learnings from the previous milestone, and it's exciting that the work is now underway. It's really important to state that sales is our focus, but to keep being known and viewed as leading edge, you have to stay constantly on top of things, be able to supply data, validate that data, and demonstrate scale-up and commercialisation capabilities. That was in now in turning down the Queensland grant. We've essentially established contracts with highly reputable labs that are very well equipped. You asked about the timing for that — it's in progress. It definitely is in progress, and that's a good thing.

Operator

operator
#39

Great, just two more questions from me. Is there a portion of the rapidly growing e-bike market that you believe could make headway over a shorter timeframe?

Merrill Gray

executive
#40

I'm personally quite excited about e-mobility, I really am. We've got to figure out a route forward, and that's the reason we're looking to partner with TRQ and Oztrade, especially in India — because anyone who operates in that area will know that India is, well, India stands out when it comes to market size and the capabilities there, yet there's actually a fair amount of Chinese technology present when it comes to battery technology. I'm fairly optimistic that via the South Korean angle, we could identify a bespoke e-mobility business based in India that we might be able to leverage off. So the answer is yes, it is a focus. We haven't quite managed to get the pathway through, but I do see some potential there, yes.

Operator

operator
#41

Thanks a lot, Merrill. If we take it that Black Diamond Structures is one of the two ABT companies currently in negotiations, could you clarify whether that second company is in chemicals, in batteries, or something else?

Merrill Gray

executive
#42

Weon is clearly part of that as well, and that, I believe, is what answers that question.

Operator

operator
#43

All right, that's ideal. This isn't a plant. It's a question that came in, really more of a statement than a question. I just wanted to express how thrilled we are, as a collective group of large shareholders, that you've taken on the CEO role on a permanent basis. We might wrap up right there, Merrill. Very well done indeed. I'll just pass it back to you for closing remarks.

Merrill Gray

executive
#44

Much appreciated. Those are generous remarks, and I truly value them. I'd like to express my gratitude to everyone for being here, and also for the backing you've given. I'm eager to collaborate with the team and to put in tremendous effort. This is an extremely dedicated group, and I look forward to demonstrating what we're truly capable of and delivering meaningful value to shareholders. That prospect excites me. Once more, many thanks for joining us today.

Operator

operator
#45

Okay, many thanks, Merrill. I’ll just remind everyone that the session was recorded and can be accessed through the link you used to register. We appreciate your being here, and thank you so much, Merrill. Nicely done. Thanks.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AnteoTech Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to AnteoTech Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in AnteoTech Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.